RxDoctor Payments Data

Tristan Bice, MD

Hematology & Oncology · Vancouver, WANPI 1912369190

Payments from drug & device makers

$216,199in general payments, 2019–2025

Across 66 payments — averaging $3275.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$96K
  • Janssen Research & Development, LLC$50K
  • Beone Medicines Ltd.$34K
  • E.r. Squibb & Sons, L.L.C.$33K
  • Astellas Pharma US Inc$948
  • Eli Lilly$609
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$2,34265%
  • Education$1,28235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$216,199 in reported general payments places this provider in the 70th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$1,752,047
Medicare patients
409
Services billed
98,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate52$713,651
TasignaNilotinib Hcl13$250,118
WeliregBelzutifan12$242,036
VenclextaVenetoclax16$236,879
Abiraterone Acetate168$218,845
Lenalidomide19$218,480
BrukinsaZanubrutinib13$203,096
IbrancePalbociclib14$145,227
EliquisApixaban22$17,984
XareltoRivaroxaban13$15,765
Hydroxyurea39$1,181
Prednisone189$726
Dexamethasone52$629
Acyclovir33$584
Anastrozole12$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$229$713,65152 claims
MerckWelireg$18$242,03612 claims
AbbVieVenclexta$106$236,87916 claims
Beigene USA, Inc.Brukinsa$109$203,09613 claims
Johnson & JohnsonXarelto$100$15,76513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 349 hematology & oncology providers in Washington.

Other hematology & oncology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →